Strategic Acquisition History Leverage Armo Biosciences’ acquisition by Eli Lilly in 2018 and subsequent public market history to position partnerships or licensing discussions with Lilly or other large pharma as potential exit strategies or co-development opportunities.

Immuno-Oncology Focus Target discussions around immuno-oncology capabilities, particularly AM0010 (pegilodecakin) and related pipeline, to offer supportive CRO, biomarker, or combination trial services that align with late-stage cancer programs.

Funding Readiness Utilize the company’s funding level and historical IPO momentum to propose strategic investment or grant-backed collaborations, as well as advisory services for scaling, clinical operations, or in-licensing discussions with larger biotechs.

Small Team, High Agility With an extremely small workforce, present scalable outsourcing models, advisory support, and rapid-development partnerships to accelerate trial execution, data analytics, and regulatory prep for late-stage IO programs.

Digital & Analytics Readiness Capitalize on the existing tech stack (Drupal, Google Analytics, New Relic, etc.) to propose digital transformation, data management, and real-world evidence (RWE) capture solutions for clinical trial sites, investor communications, and product commercialization.